source
- Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to KeytrudaAkeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China. The trial showed an improvement in o…
- AstraZeneca highlights broad oncology portfolio at ESMO conferenceAt the European Society for Medical Oncology (ESMO) meeting in Madrid, AstraZeneca used the platform to showcase its cancer research. The company presented data on both established medicines and n…